Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CGP 79787; PTK 787; PTK/ZK; vatalanib-succinate; ZK 222584

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma; Novartis
  • Developer Novartis
  • Class Antineoplastics; Phthalazines; Pyridazines; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Macrophage colony stimulating factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Colorectal cancer; Glioblastoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours

Most Recent Events

  • 29 May 2008 Novartis Pharmaceuticals in collaboration with Dana-Farber Cancer Institute terminates a phase I trial in Solid tumors in the US (NCT00358163)
  • 29 Apr 2008 Discontinued - Phase-I for Ovarian cancer in Germany (PO)
  • 29 Apr 2008 Discontinued - Phase-I for Renal cancer in Germany (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top